Capnia, Inc. develops and commercializes therapeutics and diagnostics products. The company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition that causes long-term developmental disability due to degradation of red blood cells. It also develops Serenz, a therapeutic product candidate that has completed Phase II clinical trials for the treatment of symptoms related to allergic rhinitis. The company was founded in 1999 and is based in Redwood City, California.
Trade Type
| ReliabilityScore™
| Entry Date
| Entry Price
| Sell Date
| Sell Price
| Net Gain
| Hold Time
|